A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes.

Subcutaneous semaglutide was initiated in all participants at a dose of 0.25 mg given once weekly, and the dose was titrated every 4 weeks to 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg (target dose ...

Semaglutide and related weight-loss medications ... Visceral fat, or adipose tissue, within the abdomen is more strongly associated with health problems than subcutaneous fat under the skin. The ...

Novo Nordisk, a leading global healthcare company, announced that the US Food and Drug Administration (FDA) accepted its New Drug Application (NDA) submission for an investigational once-daily, 25 mg ...

A subcutaneous formulation of MSD's top-selling cancer immunotherapy, Keytruda, was non-inferior to the current intravenous version in a head-to-head trial, setting up regulatory filings.

A formulation of MSD's cancer drug Keytruda that can be given by subcutaneous injection rather than intravenous infusion has cleared a phase 3 trial, setting up approvals later this year.

Pharmacokinetic Properties of PPIs While the half-life time of PPIs is rather similar, differences in the maximal plasma concentrations and in the area under the plasma concentration-time curve ...

PLAINSBORO, NJ, USA I April 30, 2025 I Today, The New England Journal of Medicine (NEJM) published results from part 1 of the ongoing phase 3 ESSENCE trial which investigated the effects of ...